Why the study?
While low-dose aspirin has an established role in secondary prophylaxis of CVD, its role in primary prophylaxis is debatable given an increased risk of bleeding.
Does low-dose aspirin prevent cardiovascular disease when used for primary prophylaxis?
Does low-dose aspirin prevent cardiovascular disease when used for primary prophylaxis?
The use of aspirin for primary prophylaxis of coronary artery disease remains debatable due to the associated bleeding risks.
Answers are grounded in this paper and cite their sources.
Cautions against routine low-dose aspirin for primary CVD prevention; leaves open individualized net-benefit assessment in updated trials.
Aspirin, a nonsteroidal anti-inflammatory drug, inhibits thromboxane A 2 synthesis in platelets and prevents platelet aggregation. It is commonly employed as an antiplatelet drug in cardiovascular diseases (CVD). CVDs are no longer limited to the elderly group; the incidence of myocardial infarction has increased in the young adult population too. Low-dose aspirin (75–325 mg/day) has an established role in secondary prophylaxis of CVD, but its role in primary prophylaxis is debatable. It increases the risk of bleeding. Therefore, it is an attempt to understand the therapeutic status of aspirin as a prophylactic drug, and hence, this review is needed to understand its role.
No takes yet. Share an insight, caveat, or question.
Manak et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: